نتایج جستجو برای: 90y ibritumomab tiuxetan

تعداد نتایج: 879  

2015
Sofia H. L. Frost Shani L. Frayo Brian W. Miller Johnnie J. Orozco Garrett C. Booth Mark D. Hylarides Yukang Lin Damian J. Green Ajay K. Gopal John M. Pagel Tom A. Bäck Darrell R. Fisher Oliver W. Press

PURPOSE Pretargeted radioimmunotherapy (PRIT) is a multi-step method of selectively delivering high doses of radiotherapy to tumor cells while minimizing exposure to surrounding tissues. Yttrium-90 (90Y) and lutetium-177 (177Lu) are two of the most promising beta-particle emitting radionuclides used for radioimmunotherapy, which despite having similar chemistries differ distinctly in terms of r...

Journal: :Issues in emerging health technologies 2007
C Allison

(1) Microspheres containing radioactive yttrium-90 (90Y) are infused into the hepatic artery. These deliver high doses of ionizing radiation to inoperable hepatocellular carcinoma, the most common type of primary liver cancer. (2) Limited evidence from several case series indicates that palliative therapy with 90Y microspheres may reduce tumour size and increase survival time. (3) In some patie...

Journal: :Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2011
Vanessa L Gates Abdulredha A H Esmail Karen Marshall Stewart Spies Riad Salem

UNLABELLED Radioembolization with 90Y microspheres represents a novel transarterial radiation treatment for liver tumors. The purpose of this pilot study was to evaluate the findings of postimplantation PET/CT of 90Y glass microspheres. METHODS Three patients with hepatocellular carcinoma and 2 patients with liver metastases (1 neuroendocrine, 1 colorectal) underwent PET/CT after radioemboliz...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 1996
N Deb M Goris K Trisler S Fowler J Saal S Ning M Becker C Marquez S Knox

A Phase I dose-escalation study using 90Y-CYT-356 monoclonal antibody was performed in 12 patients with hormone-refractory prostate carcinoma. Biodistribution studies using 111In-CYT-356 were performed 1 week before 90Y-CYT-356 administration. Of the 12 patients, 58% had at least one site of disease imaged after administration of 111In-CYT-356. The dose of 90Y ranged from 1.83-12 mCi/m2. Both 1...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید